medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Number 1

<< Back Next >>

Ann Hepatol 2014; 13 (1)

Primary prophylaxis with ciprofloxacin in cirrhotic patients with ascites: a randomized, double blind study

Téllez-Ávila F, Sifuentes-Osornio J, Barbero-Becerra V, Franco-Guzmán A, Ruiz-Cordero R, Alfaro-Lara R, Hernández-Ramírez Á, Vargas-Vorácková F

Language: English
References: 31
Page: 65-74
PDF size: 123.94 Kb.


ABSTRACT

Introduction and aim. There is scarce information about primary prophylaxis in cirrhotic patients. The aim was to assess the efficacy of ciprofloxacin for primary prophylaxis for bacterial infections in patients with cirrhosis of the liver and ascites. Material and methods. A randomized, double-blind placebo-controlled clinical trial was conduced. Patients were randomized to receive oral ciprofloxacin 500 mg/day or placebo for one month. A basal evaluation and repeated assessments at 4, 6, 12, 18, and 24 weeks afterwards, or whenever a primary endpoint occurred were done. Statistical analysis: probability curves were constructed with the Kaplan-Meier method and compared by the log-rank test. Results. 95 patients were randomized to ciprofloxacin group (n = 49; 51.6%) and placebo group (n = 46; 48.4%). Six-teen (32.6%) patients in the ciprofloxacin group developed bacterial infections and thirteen (28.2%) patients developed bacterial infections in the placebo group (p = NS). The probability to remain free of bacterial infections did not reach statistical significance (p = 0.38). Probability of survival at 24 weeks was 91% in placebo group and 98% in the ciprofloxacin group (p = 0.28). The absolute risk reduction was 5%, the relative risk reduction was 6% and the NNT was 20 patients. Conclusion. Primary prophylaxis with ciprofloxacin for one month in cirrhotic patients with ascites who do not have a currently accepted indication, did not show a preventive effect on the development of bacterial infections at one month follow-up. Moreover in women could increases the odds for UTI. The administration of ciprofloxacin seemed to decrease the risk of mortality.


REFERENCES

  1. Wong F, Bernardi M, Balk R, Christman B, Moreau R, Garcia- Tsao G, Patch D, et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut 2005; 54: 718-25.

  2. Arvaniti V, D’Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, Borroughs AK. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246-56.

  3. Gines P, Rimola A, Planas R, Vargas V, Marco F, Almela M, Forné M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double- blind, placebo-controlled trial. Hepatology 1990; 12: 716-24.

  4. Terg R, Fassio E, Guevara M, Cartier M, Longo C, Lucero R, Landeira C, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo- controlled study. J Hepatol 2008; 48: 774-9.

  5. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del- Arbol L, Castells L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-9.

  6. Novella M, Sola R, Soriano G, Andreu M, Gana J, Ortiz J, Coll S, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997; 25: 532-6.

  7. Grange JD, Roulot D, Pelletier G, Pariente EA, Denis J, Ink O, Blanc P, et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J Hepatol 1998; 29: 430-6.

  8. Fernandez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Villa C, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-24.

  9. Loomba R, Wesley R, Bain A, Csako G, Pucino F. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 487-93.

  10. Tito L, Rimola A, Gines P, Llach J, Arroyo V, Rodes J. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988; 8: 27-31.

  11. Silvain C, Besson I, Ingrand P, Mannant PR, Fort E, Beauchant M. Prognosis and long-term recurrence of spontaneous bacterial peritonitis in cirrhosis. J Hepatol 1993; 19: 188-9.

  12. Terg R, Levi D, Lopez P, Rafaelli C, Rojter S, Abecasis R, Villamin F, et al. Analysis of clinical course and prognosis of culture-positive spontaneous bacterial peritonitis and neutrocytic ascites. Evidence of the same disease. Dig Dis Sci 1992; 37: 1499-504.

  13. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, Soares-Weiser K, Mendez-Sanchez N, Gluud C, Uribe M. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review. Aliment Pharmacol Ther 2011; 34: 509-18.

  14. Llach J, Rimola A, Navasa M, Gines P, Salmeron JM, Gines A, Rodés J. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology 1992; 16: 724-7.

  15. Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986; 91: 1343-6.

  16. Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, Rodés J. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35: 140-8.

  17. Barahona-Garrido J, Hernandez-Calleros J, Tellez-Avila FI, Chavez-Tapia NC, Remes-Troche JM, Torre A. Bacterial meningitis in cirrhotic patients: case series and description of the prognostic role of acute renal failure. J Clin Gastroenterol 2010; 44: 218-23.

  18. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001; 120: 726-48.

  19. Garcia-Tsao G. Spontaneous bacterial peritonitis: a historical perspective. J Hepatol 2004; 41: 522-7.

  20. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999; 29: 745-58.

  21. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005; 40: 643-54.

  22. Mandell LA, Bartlett JG, Dowell SF, File TM Jr., Musher DM, Whitney C, Infectious Diseases Society of America. Update of practice guidelines for the management of communityacquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-33.

  23. Albillos A, De-la-Hera A, Alvarez-Mon M. Serum lipopolysaccharide- binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet 2004; 363: 1608-10.

  24. Soriano G, Guarner C, Teixido M, Such J, Barrios J, Enriquez J, Vilardell F. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991; 100: 477-81.

  25. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999; 29: 1655-61.

  26. Chavez-Tapia NC, Torre-Delgadillo A, Tellez-Avila FI, Uribe M. The molecular basis of susceptibility to infection in liver cirrhosis. Curr Med Chem 2007; 14: 2954-8.

  27. Barbero-Becerra VJ, Gutierrez-Ruiz MC, Maldonado-Bernal C, Tellez-Avila FI, Alfaro-Lara R, Vargas-Vorackova F. Vigorous, but differential mononuclear cell response of cirrhotic patients to bacterial ligands. World J Gastroenterol 2011; 17: 1317-25.

  28. Zhang LJ, Wang XZ. Interleukin-10 and chronic liver disease. World J Gastroenterol 2006; 12: 1681-5.

  29. Tilg H, Kaser A, Moschen AR. How to modulate inflammatory cytokines in liver diseases. Liver Int 2006; 26: 1029-39.

  30. Berry PA, Antoniades CG, Hussain MJ, McPhail MJ, Bernal W, Vergani D, Wendon JA. Admission levels and early changes in serum interleukin-10 are predictive of poor outcome in acute liver failure and decompensated cirrhosis. Liver Int 2010; 30: 733-40.

  31. Albillos A, de la Hera A, Gonzalez M, Moya JL, Calleja JL, Monserrat J, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37: 208-17.




2020     |     www.medigraphic.com